US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Invesco Dorsey Wright Healthcare Momentum ETF

61.45

+0.52160.86%

Post-market: 61.450.00000.00%16:10 EDT

Volume:192.56K

Turnover:11.76M

Market Cap:271.61M

PE:20.10

High:62.12

Open:61.37

Low:60.40

Close:60.93

52wk High:64.10

52wk Low:39.36

Shares:4.42M

Float Shares:4.42M

Volume Ratio:6.46

T/O Rate:4.36%

Dividend:1.53

Dividend Rate:2.48%

EPS(TTM):3.06

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation

Revolution Medicines, Inc. : Needham Raises Target Price to $275 from $240

THOMSON REUTERS

Guangdong Hybribio Biotech's Subsidiary Secures In Vitro Diagnostic Device Registration Certificate

Does Guardant Health’s (GH) Patent Appeal Reshape Its Competitive Moat More Than Its Royalty Bill?

Simply Wall St.

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Spyre Therapeutics (SYRE)

Pharma Industry Stares Down Biggest Patent Cliff in Decades

Immunovant Director Atul Pande Disposes of 1,500 Common Shares Worth $64,905

Revolution Medicines Set to Post 'Strong Launch' for Rasonque, UBS Says

MT Newswires Live

Roivant Sets Price for New Rare Disease Drug Lisraya at $35,000 a Month

Lisraya is Commercially Available NOW - Roivant Presentation

THOMSON REUTERS

Roivant Sciences Exec Says Lisraya Will be Available at List Price of $35,000 for a 30-Day Supply

THOMSON REUTERS

Roivant Sciences Price Target Maintained with a $41.00/Share by HC Wainwright & Co.

US Regulator Approves Novel Pancreatic Cancer Therapy, Marking Major Win for Independent Biotech

Why the Drugmaker Behind a Pancreatic Cancer Breakthrough Stayed Independent

Roivant Sciences Gets FDA Approval for LISRAYA in Dermatomyositis; Shares Rise

MT Newswires Live

Priovant Therapeutics - Lisraya NOW Available in the U.S.

THOMSON REUTERS

Priovant Announces FDA Approval of Lisraya™ (Brepocitinib) for Adults with Dermatomyositis; NOW Available in the U.S.

THOMSON REUTERS

US FDA Approves Roivant-Priovant's Skin Disease Drug

FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults

FDA: Lisraya is the First FDA-Approved Oral Treatment Option for Patients with Dermatomyositis

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/PTH/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PTH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTH\",,,,,undefined,":{"symbol":"PTH","market":"US","secType":"STK","nameCN":"Invesco Dorsey Wright Healthcare Momentum ETF","latestPrice":61.45,"timestamp":1788379200000,"preClose":60.9284,"halted":0,"volume":192562,"hourTrading":{"tag":"盘后","latestPrice":61.45,"preClose":61.45,"latestTime":"16:10 EDT","volume":9,"amount":553.0500000000001,"timestamp":1788379804937,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.008560868166569275,"floatShares":4420000,"shares":4420000,"eps":3.057033,"marketStatus":"Post-Mkt","change":0.5216,"latestTime":"09-02 19:02:24 EDT","open":61.3732,"high":62.12,"low":60.4,"amount":11760278,"amplitude":0.02823,"askPrice":62.07,"askSize":4800,"bidPrice":60.83,"bidSize":4900,"shortable":3,"etf":1,"ttmEps":3.057033,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1788393600000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":60.9284,"sharesOutstanding":2480000,"nav":60.75388,"aum":269747227.2,"dividendRate":0.024845,"bidAskSpread":0.001923,"preHourTrading":{"tag":"盘前","latestPrice":60.9284,"preClose":60.9284,"latestTime":"07:36 EDT","volume":3,"amount":182.7852,"timestamp":1788348989320,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":61.45,"preClose":61.45,"latestTime":"16:10 EDT","volume":9,"amount":553.0500000000001,"timestamp":1788379804937,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":6.461639,"impliedVol":0.116,"impliedVolPercentile":0.4405},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTH\",,,,,undefined,":{"symbol":"PTH","floatShares":4420000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":6.461639,"shares":4420000,"dividePrice":1.5267,"high":62.12,"amplitude":0.02823,"preClose":60.9284,"low":60.4,"week52Low":39.36,"pbRate":"--","week52High":64.1,"institutionHeld":0,"latestPrice":61.45,"committee":0.010309,"eps":3.057033,"divideRate":0.024845,"volume":192562,"delay":0,"ttmEps":3.057033,"open":61.3732,"prevYearClose":49.701,"prevWeekClose":61.0661,"prevMonthClose":60.7941,"prevQuarterClose":59.76,"fiveDayClose":63.629,"twentyDayClose":60.0964,"sixtyDayClose":48.9492},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PTH\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"PTH","amount":1.52645,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Invesco Dorsey Wright Healthcare Momentum ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2024-06-24","symbol":"PTH","amount":0.02545,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-24","defaultRemindTime":1719235800000,"name":"Invesco Dorsey Wright Healthcare Momentum ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-28","payableDate":"2024-06-24","currency":"USD","dateTimestamp":1719201600000,"payDate":"2024-06-28"},{"market":"US","date":"2023-07-17","symbol":"PTH","defaultRemindTime":1689600600000,"type":"split","dateTimestamp":1689566400000,"forFactor":1,"toFactor":3,"ratio":0.3333333333333333}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PTH\",market:\"US\",,,undefined,":[{"executeDate":"2024-06-24","recordDate":"2024-06-24","paymentDate":"2024-06-28","value":0.02545,"currency":"USD"},{"executeDate":"2025-12-22","recordDate":"2025-12-22","paymentDate":"2025-12-26","value":1.52645,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PTH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PTH\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2663077311","title":"Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation","url":"https://stock-news.laohu8.com/highlight/detail?id=2663077311","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663077311?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:00","pubTimestamp":1788174000,"startTime":"0","endTime":"0","summary":"NEW YORK, Aug.  31, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/31/3353172/33090/en/axsome-therapeutics-initiates-summit-phase-3-trial-of-axs-05-in-smoking-cessation.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNS","BK4585","LU2324357040.USD","BK4505","PTH","BK4135","BK4007","AXSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663079265","title":"Revolution Medicines, Inc. : Needham Raises Target Price to $275 from $240","url":"https://stock-news.laohu8.com/highlight/detail?id=2663079265","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663079265?lang=en_us&edition=fundamental","pubTime":"2026-08-31 17:45","pubTimestamp":1788169510,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nFWN44S00C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0889565916.HKD","IE0002141913.USD","LU0320765992.SGD","RVMD","IDNA","BK4139","IE0009354923.USD","IE00BJT1NW94.SGD","IE0009355771.USD","BBH","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","LU0109394709.USD","CANC","PTH","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115184678","title":"Guangdong Hybribio Biotech's Subsidiary Secures In Vitro Diagnostic Device Registration Certificate","url":"https://stock-news.laohu8.com/highlight/detail?id=1115184678","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115184678?lang=en_us&edition=fundamental","pubTime":"2026-08-31 16:40","pubTimestamp":1788165635,"startTime":"0","endTime":"0","summary":"Guangdong Hybribio Biotech Co., Ltd. (300639.SZ) announced that its wholly-owned subsidiary, Chaozhou Kaipu Bio-Chemistry Co., Ltd. (referred to as \"Kaipu Chemistry\"), has recently obtained the...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IEIH","MDEV","159883","PTH","300639","LGHT","LNGR","BK0042","GDOC","BK1574","AGNG","MEDX","BK0132","HART","BK1100","RSPH","BK0239","09996","BK1583","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663044590","title":"Does Guardant Health’s (GH) Patent Appeal Reshape Its Competitive Moat More Than Its Royalty Bill?","url":"https://stock-news.laohu8.com/highlight/detail?id=2663044590","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663044590?lang=en_us&edition=fundamental","pubTime":"2026-08-30 19:19","pubTimestamp":1788088793,"startTime":"0","endTime":"0","summary":"In August 2026, Guardant Health said it would appeal a US District Court of Delaware final judgment in a patent dispute with TwinStrand Biosciences and the University of Washington, with execution of the judgment and collection of potential royalties paused during the appeal.\nThe court’s royalty order applies mainly to older Guardant tests, while Guardant reports that upgraded versions of key products such as Shield and Reveal, along with validated design changes to Guardant360, fall outside...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6032000-choice2-main-header/1585186864566","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6032000-choice2-main-header/1585186864566"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/does-guardant-healths-gh-patent-appeal-reshape-its-competiti","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/does-guardant-healths-gh-patent-appeal-reshape-its-competiti","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4551","EKG","FFOX","LU0109394709.USD","GNOM","BK4585","HELX","LU0320765992.SGD","GDOC","GH","LFSC","PTH","GNMX","BK4196","BK4588","BK4535","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663464017","title":"Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Spyre Therapeutics (SYRE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2663464017","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663464017?lang=en_us&edition=fundamental","pubTime":"2026-08-29 22:30","pubTimestamp":1788013830,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Revolution Medicines (RVMD) and Spyre Therapeutics (...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-revolution-medicines-rvmd-and-spyre-therapeutics-syre-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-revolution-medicines-rvmd-and-spyre-therapeutics-syre-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","XBI","BK4139","SYRE","LFSC","IE00BJJMRZ35.SGD","IE0002141913.USD","LU0109394709.USD","XLV","HCSG","IDNA","LABU","PTH","BK4588","LU0320765992.SGD","IE0009355771.USD","IE00B4R5TH58.HKD","CANC","LU0889565916.HKD","IE0009354923.USD","RVMD","BK4581","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","BK4585","BBH","IE00BJT1NW94.SGD","LU0029874061.USD","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663019778","title":"Pharma Industry Stares Down Biggest Patent Cliff in Decades","url":"https://stock-news.laohu8.com/highlight/detail?id=2663019778","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663019778?lang=en_us&edition=fundamental","pubTime":"2026-08-29 09:00","pubTimestamp":1787965200,"startTime":"0","endTime":"0","summary":"Most companies sell a hit product for as long as customers want it. For drugmakers, a clock starts before a drug is even approved: Patents run out, lower-priced copycats flood in and sales collapse. B","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999015986.USD","VHT","LU1883839398.USD","LU0320765489.SGD","IHE","LU0320765646.SGD","LU0980610538.SGD","GLAM","LU1037948541.HKD","LU0267386448.USD","LU1989772923.USD","LU0683600562.USD","LU2357305700.SGD","LU0203345920.USD","SG9999015952.SGD","LU1548497426.USD","LU1162221912.USD","LU0477156953.USD","LU2491050154.USD","IE00BGHQF631.EUR","RXL","LU1720051017.SGD","RVMD","SG9999014559.SGD","LU1244550494.USD","BK4548","LU0154236417.USD","LU0323591593.USD","LU1979441026.SGD","LU0471298777.SGD","LU1496350171.SGD","LU2111349929.HKD","LU0237698245.USD","LU0256863902.USD","IE00B19Z3581.USD","GDOC","LU0859254822.USD","LU0306806265.USD","BK4566","IE00BFSS8Q28.SGD","LU0823434583.USD","BK4533","LU1032466523.USD","BK4599","LU2456880835.USD","BK4559","LU0057025933.USD","LU1839511570.USD","LU0289961442.SGD","LU1670711040.USD","BBH","IE00BKDWB100.SGD","LU0097036916.USD","NVOX","LU1989771016.USD","IE00B4JS1V06.HKD","LU0354030511.USD","LU2125154935.USD","LU0820562030.AUD","LU0889565916.HKD","GNOM","MEDI","LU0472753341.HKD","LU1267930490.SGD","LU1236620750.USD","SGXZ81514606.USD","LU0471298694.HKD","IE00B1BXHZ80.USD","LU0942090050.USD","SGXZ31699556.SGD","LU2125909247.SGD","LU0289739343.SGD","BK4532","LU1732800096.USD","IE00BBT3K403.USD","LU0208291251.USD","LU2125909593.SGD","WDNA","NVOH","SGXZ51526630.SGD","IE00BSNM7G36.USD","LU1929549753.HKD","IE00BFSS7M15.SGD","SG9999001176.USD","IE00BLSP4452.SGD","LU0545039389.USD","IYH","BK4139","LU0211328371.USD","LU2023250843.SGD","MRK","LU0006306889.USD","SG9999015358.SGD","IE00BWXC8680.SGD","IE000BZT7R73.USD","LU2028103732.USD","LU2756315664.SGD","LU1145028129.USD","LU0949170772.SGD","IE00BKPKM429.USD","LU2237443465.HKD","LU0320765992.SGD","LU2602419157.SGD","LU1868837136.USD","LU1074936037.SGD","SG9999002224.SGD","LU2213496289.HKD","BK4588","LU2552382132.HKD","LU0786609619.USD","LU1066051225.USD","MRNX","LU0985320562.USD","LU0238689110.USD","LU1066051498.USD","LU1093756325.SGD","PJP","LU1868836591.USD","CURE","LU0823416689.USD","LU0640476718.USD","IE0002270589.USD","LU0130517989.USD","LU0868494617.USD","LU1923622614.USD","LU0289739699.SGD","IXJ","LU0321505868.SGD","LU2023250504.SGD","IE00B4R5TH58.HKD","LU1037948897.HKD","BK4581","LU1366192091.USD","LU0882574055.USD","LU1035773651.USD","LU0708994859.HKD","LU1814569148.SGD","LU2133065610.SGD","LU0203202063.USD","LU0795875169.SGD","LU0820561818.USD","LU2361044949.HKD","LU1551013342.USD","LU2236285917.USD","LU2896262040.SGD","HRTS","FHLC","LU0395794307.EUR","LGHT","LU2112291526.USD","IE00BJT1NW94.SGD","IE0002141913.USD","IE000SO60NU8.SGD","LU0096364046.USD","IE0000B7K699.USD","LU1868837300.USD","LU2129689431.USD","LU0787776722.HKD","AGNG","LU0316494557.USD","IE00BFTCPJ56.SGD","BMED","LU2242646821.SGD","LU0321505439.SGD","LU2089984988.USD","LU0069063385.USD","LU2023250330.USD","LU0225771236.USD","IE00B3PB1722.GBP","LU0310800379.SGD","LU1941712264.USD","SG9999014575.USD","LU0354030438.USD","LU0965509101.SGD","MRNA","LU0158827948.USD","IE00BJJMRZ35.SGD","LU2271345857.HKD","SG9999014542.SGD","LU1712237335.SGD","LU2552382058.USD","LLYZ","LU1934455277.USD","LU1291159041.SGD","LU2471134952.CNY","LU0553294199.USD","IE00BVYPNV92.GBP","LU0965509010.AUD","LU0708995401.HKD","LU2347655156.SGD","SG9999017495.SGD","LU0122379950.USD","LU1989772840.SGD","LU2746668461.USD","LU1988902786.USD","LU1244550221.USD","LU0058720904.USD","LU1551013425.SGD","LU2168564149.EUR","FTXH","BK4550","LU2417539215.USD","LU2168564222.USD","LU0965508806.USD","LU2242652126.USD","SG9999014914.USD","LU2237443382.USD","LU0964807845.USD","LU2237443895.HKD","LU0256863811.USD","LU1430594728.SGD","LU0079474960.USD","LU1267930573.SGD","LU0320765059.SGD","LU0306807586.USD","LU2750360641.GBP","SG9999001176.SGD","LU0738911758.USD","LU1236620834.HKD","JDOC","IE00B775H168.HKD","LU0210536198.USD","LU1069347547.HKD","LU1934455194.USD","TRUH","ILDR","SGXZ57979304.SGD","LU0689472784.USD","LU0795875086.SGD","LU0266013472.USD","LU2756315318.SGD","LU1629891620.HKD","ELIL","LU0234570918.USD","LU2360032135.SGD","BK4501","LU2462157665.USD","LU0211327993.USD","SGXZ99366536.SGD","LU2468319806.SGD","BK4585","PPH","LU1670628061.USD","LU1670711123.USD","LU1116320901.HKD","LU1066053197.SGD","BK4534","LU2063271972.USD","LU0170899867.USD","BK4007","LU1934455863.HKD","LU2264538146.SGD","IE00BK4W5L77.USD","LU2211815571.USD","LU0861579265.USD","IE00BJJMRX11.SGD","LU1804176565.USD","CANC","LU2746668974.SGD","SG9999011175.SGD","LU1201861249.SGD","LU1280957306.USD","LU0070302665.USD","MEDX","LU1868836757.USD","MRNY","LU0353189680.USD","LU1035775433.USD","LU1670710588.SGD","LU2491049909.HKD","LU2237443622.USD","IE0009354923.USD","LU0098860793.USD","IE000MB6IJN5.SGD","LU0114720955.EUR","LLYX","LU0385154629.USD","IE00BN29S564.USD","LU0029864427.USD","LU2089284900.SGD","LU2596442595.SGD","LU0211331839.USD","IDNA","LU2087625088.SGD","LU2750360997.AUD","LU0466842654.USD","SG9999001440.SGD","LU1623119135.USD","LU0985481810.HKD","LU1699723380.USD","LU2108987350.USD","LU2471134523.USD","LU0198837287.USD","XLV","IE00BN8TJ469.HKD","LU0820561909.HKD","LU2361045086.USD","LU1496350502.SGD","LU1720051108.HKD","LU2265009873.SGD","SG9999003800.SGD","LU0726765562.USD","THNR","LU0882574139.USD","LU2433249047.HKD","LU0130102774.USD","IE0005OL40V9.USD","LU2237438978.USD","LU0511384066.AUD","BK4551","PAWZ","LU1917777945.USD","LLII","LU1974910355.USD","LU0265550359.USD","LU1323610961.USD","LU2360106947.USD","LU1670710661.SGD","NVOC","IE00BJJMRY28.SGD","LU0648001328.SGD","IE00BLSP4239.USD","LU1066051811.HKD","LU1232071149.USD","IE000M9KFDE8.USD","PTH","LU2129689514.USD","LU2552382215.SGD","LU0061475181.USD","LU0174119429.USD","ELIS","IE00B1XK9C88.USD","ABBV","IE00BFXG1179.USD","SG9999018865.SGD","LU0203347892.USD","SG9999014898.SGD","LU2471134796.USD","LU2089283258.USD","IE0001KFT4U8.USD","IE00BDGV0183.EUR","LU0456855351.SGD","LU2324357040.USD","SG9999002232.USD","LU2347655073.USD","LU0689626769.HKD","LU1116320737.USD","LU1941712348.USD","LU2023251221.USD","LU0417517546.SGD","LU2168563687.JPY","LU2361044865.SGD","LU0345770993.USD","LU1244550577.SGD","LU1670627923.USD","LU2237443978.SGD","IE00BJLML261.HKD","LU1868836914.USD","LU0345770308.USD","LU0124676726.USD","BK4568","LU2462591350.SGD","LU0158827781.USD","BMY","SG9999015341.SGD","LU2129689605.HKD","IE0004445239.USD","SG9999015978.USD","IE00B2B36J28.USD","LU2106854487.HKD","LU1571399168.USD","SG9999018857.SGD","LU1718418525.SGD","MHIP","LU0203201768.USD","LU0106261372.USD","LU2471134879.HKD","LU0912757837.SGD","SG9999014906.USD","LU1069344957.HKD","LU2168564495.EUR","LU2087621335.USD","LU0234572021.USD","IE00BZ1G4Q59.USD","LU0109394709.USD","NVO","LU0432979614.USD","LU2168564065.EUR","BK4516","LU0109391861.USD","IE00BKVL7J92.USD","IE00B42XCP33.USD","TMED","OZEM","LLY","LU1003077747.HKD","LU0133085943.USD","LU0868494708.USD","LU0128525929.USD","LU0225284248.USD","IE000WAW04H5.SGD","LU0353189763.USD","LU2125154778.USD","IE000F7OJYX1.SGD","LU0310799852.SGD","LU1061106388.HKD","LU2237443549.SGD","LU1261432733.SGD","LU1023059063.AUD","LU1983299246.USD","GB00BDT5M118.USD","SG9999014880.SGD","LU0225283273.USD","LU1691799644.USD","IE00BK4W5M84.HKD","LU0661504455.SGD","IE00BVYPNW00.USD","LU1585245621.USD","IE00B19Z3B42.SGD","LU1732799900.SGD","SG9999013999.USD","LU0943347566.SGD","SG9999015945.SGD","LU1093756168.USD","IE00B7KXQ091.USD","LU0672654240.SGD","SG9999014567.USD","LU0965509283.SGD","LU2461242641.AUD","LU0094547139.USD","LU1064131342.USD","LU1127390331.HKD","LU0265550946.USD","LU1057294990.SGD","IE0009355771.USD","LU2491050071.SGD","LU0823434740.USD","LU1267930730.SGD","LU2357627491.SGD","IE0004445015.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663013728","title":"Immunovant Director Atul Pande Disposes of 1,500 Common Shares Worth $64,905","url":"https://stock-news.laohu8.com/highlight/detail?id=2663013728","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663013728?lang=en_us&edition=fundamental","pubTime":"2026-08-29 04:29","pubTimestamp":1787948961,"startTime":"0","endTime":"0","summary":"Immunovant director Atul Pande disposes of 1,500 common shares worth $64,905Immunovant director Atul Pande exercised stock options for 1,500 shares at $8.43 on Aug. 28, 2026.He sold 1,500 shares at $4","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nNDLRTwYM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","PTH","BK4139","ROIV","BK4007","IMVT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663975310","title":"Revolution Medicines Set to Post 'Strong Launch' for Rasonque, UBS Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2663975310","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663975310?lang=en_us&edition=fundamental","pubTime":"2026-08-29 00:18","pubTimestamp":1787933923,"startTime":"0","endTime":"0","summary":"Revolution Medicines  should post \"strong launch numbers\" for pancreatic cancer drug Rasonque , which would serve as a key driver of its 2026 and 2027 revenue, UBS Securities said in a Thursday note.The US Food and Drug Administration approved Rasonque for the treatment of adult patients with metastatic pancreatic adenocarcinoma, with the company to price the therapy at $39,800 for a 30-day supply.Street consensus for the company's 2026 and 2027 revenue already increased following the approval, but the updated projections remain achievable, UBS said. Revolution Medicines already had 2,000 patients on its expanded access program as of Q2, the brokerage noted.The consensus is for $152 million revenue in 2026 and $1.10 billion in 2027, while UBS estimates $193 million in 2026 and $1.91 billion in 2027, according to the note.UBS also noted the upcoming phase 3 data on daraxonrasib in non-small cell lung cancer by year-end 2027 as Revolution Medicines' next major clinical catalyst.UBS raise","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B2B36J28.USD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","IE0009355771.USD","IE00BJT1NW94.SGD","LU0889565916.HKD","RVMD","IE0002141913.USD","CANC","LU0109394709.USD","PTH","BBH","BK4139","IDNA","IE00BJJMRZ35.SGD","LU0320765992.SGD","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662209888","title":"Roivant Sets Price for New Rare Disease Drug Lisraya at $35,000 a Month","url":"https://stock-news.laohu8.com/highlight/detail?id=2662209888","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662209888?lang=en_us&edition=fundamental","pubTime":"2026-08-28 20:13","pubTimestamp":1787919224,"startTime":"0","endTime":"0","summary":"Roivant sets price for new rare disease drug Lisraya at $35,000 a monthAug 28 -RoivantROIV.Oand partner Priovant Therapeutics' newly approved rare disease drug Lisraya will carry a list price of $35,000 for a 30-day supply, Roivant Chief Executive Matt Gline said on an analyst call on Friday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nL4N44P0XJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","BK4007","PTH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662109816","title":"Lisraya is Commercially Available NOW - Roivant Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2662109816","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662109816?lang=en_us&edition=fundamental","pubTime":"2026-08-28 20:07","pubTimestamp":1787918848,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nFWN44P1RX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ROIV","BK4007","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662060278","title":"Roivant Sciences Exec Says Lisraya Will be Available at List Price of $35,000 for a 30-Day Supply","url":"https://stock-news.laohu8.com/highlight/detail?id=2662060278","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662060278?lang=en_us&edition=fundamental","pubTime":"2026-08-28 20:07","pubTimestamp":1787918848,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nFWN44P1RX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ROIV","PTH","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662060570","title":"Roivant Sciences Price Target Maintained with a $41.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2662060570","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662060570?lang=en_us&edition=fundamental","pubTime":"2026-08-28 19:56","pubTimestamp":1787918160,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ROIV/analyst-ratings","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","PTH","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145744656","title":"US Regulator Approves Novel Pancreatic Cancer Therapy, Marking Major Win for Independent Biotech","url":"https://stock-news.laohu8.com/highlight/detail?id=1145744656","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145744656?lang=en_us&edition=fundamental","pubTime":"2026-08-28 18:24","pubTimestamp":1787912643,"startTime":"0","endTime":"0","summary":"The U.S. Food and Drug Administration has officially approved Revolution Medicines' self-developed pancreatic cancer treatment, Rasonque, this week. This approval represents a significant triumph for...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","IDNA","LABU","IE00BJT1NW94.SGD","BK4585","IE0002141913.USD","BK4139","CANC","LU0109394709.USD","IE00BFTCPJ56.SGD","LU0889565916.HKD","BK4588","LU0320765992.SGD","PTH","IE00BJJMRZ35.SGD","RVMD","IE00B4R5TH58.HKD","BBH","IE0009354923.USD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662037671","title":"Why the Drugmaker Behind a Pancreatic Cancer Breakthrough Stayed Independent","url":"https://stock-news.laohu8.com/highlight/detail?id=2662037671","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662037671?lang=en_us&edition=fundamental","pubTime":"2026-08-28 09:21","pubTimestamp":1787880060,"startTime":"0","endTime":"0","summary":"Earlier this year, an oncology biotech with no drugs on the market-just promising research-was attracting takeover interest. Revolution Medicines stayed independent.This week, that bet paid off.The 12","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFTCPJ56.SGD","PTH","CANC","BBH","RVMD","IE0009355771.USD","LU0320765992.SGD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","LU0889565916.HKD","IE00BJJMRZ35.SGD","LU0109394709.USD","IE0009354923.USD","BK4139","IE00BJT1NW94.SGD","IDNA","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662003883","title":"Roivant Sciences Gets FDA Approval for LISRAYA in Dermatomyositis; Shares Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2662003883","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662003883?lang=en_us&edition=fundamental","pubTime":"2026-08-28 03:58","pubTimestamp":1787860715,"startTime":"0","endTime":"0","summary":"Roivant Sciences (ROIV) said Thursday the FDA approved LISRAYA for adults with dermatomyositis, with the once-daily pill now available in the US, sending its shares up 1.5%.The approval follows the Ph","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LABU","BK4585","BK4588","BK4007","PTH","ROIV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662080615","title":"Priovant Therapeutics - Lisraya NOW Available in the U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=2662080615","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662080615?lang=en_us&edition=fundamental","pubTime":"2026-08-28 03:28","pubTimestamp":1787858916,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nTUA83F05F:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PTH","BK4007","ROIV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662080613","title":"Priovant Announces FDA Approval of Lisraya™ (Brepocitinib) for Adults with Dermatomyositis; NOW Available in the U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=2662080613","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662080613?lang=en_us&edition=fundamental","pubTime":"2026-08-28 03:28","pubTimestamp":1787858916,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nTUA83F05F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ROIV","BK4139","PTH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662806990","title":"US FDA Approves Roivant-Priovant's Skin Disease Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2662806990","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662806990?lang=en_us&edition=fundamental","pubTime":"2026-08-28 03:26","pubTimestamp":1787858771,"startTime":"0","endTime":"0","summary":"US FDA approves Roivant-Priovant's skin disease drugAug 27 (Reuters)-The U.S. Food and Drug Administration said on Thursday it approved a treatment from RoivantROIV.Oand partner Priovant Therapeutics for dermatomyositis, making it the first oral drug for the skin disease.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nL4N44O1TO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTH","ROIV","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662080316","title":"FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults","url":"https://stock-news.laohu8.com/highlight/detail?id=2662080316","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662080316?lang=en_us&edition=fundamental","pubTime":"2026-08-28 03:18","pubTimestamp":1787858285,"startTime":"0","endTime":"0","summary":"BRIEF-FDA Approves First Oral Drug Indicated To Treat Dermatomyositis In AdultsAug 28 (Reuters)-FDA:FDA: FDA APPROVES FIRST ORAL DRUG INDICATED TO TREAT DERMATOMYOSITIS IN ADULTSFDA: LISRAYA IS THE FIRST FDA-APPROVED ORAL TREATMENT OPTION FOR PATIENTS WITH DERMATOMYOSITIS","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nFWN44O1ID:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ROIV","BK4007","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662803550","title":"FDA: Lisraya is the First FDA-Approved Oral Treatment Option for Patients with Dermatomyositis","url":"https://stock-news.laohu8.com/highlight/detail?id=2662803550","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662803550?lang=en_us&edition=fundamental","pubTime":"2026-08-28 03:14","pubTimestamp":1787858053,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nFWN44O1ID:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ROIV","BK4139","BK4007","PTH"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}]}}